<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02152163</url>
  </required_header>
  <id_info>
    <org_study_id>WIRB Protocol #20121749</org_study_id>
    <nct_id>NCT02152163</nct_id>
  </id_info>
  <brief_title>Assessing the Efficacy of IV Ibuprofen for Treatment of Pain in Orthopedic Trauma Patients</brief_title>
  <official_title>Assessing the Efficacy of IV Ibuprofen for Treatment of Pain in Orthopedic Trauma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Delray Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Delray Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      STUDY OBJECTIVES:&#xD;
&#xD;
        1. To evaluate the effectiveness of around the clock (OTC) IV ibuprofen (8 doses) in&#xD;
           decreasing pain in orthopedic trauma patients with fractures of the extremities, face,&#xD;
           pelvis and/or ribs compared to patients not receiving the medication.&#xD;
&#xD;
        2. To evaluate the effectiveness of around the clock (OTC) IV ibuprofen (8 doses) in&#xD;
           decreasing the use of opioid analgesics among orthopedic trauma patients with fractures&#xD;
           of the extremities, face, pelvis, and/or ribs compared to compared to patients not&#xD;
           receiving the medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients were trauma patients between the ages of 18 and 75 years old with adequate&#xD;
      IV access who were able to self-report and communicate pain severity and who were&#xD;
      consecutively admitted to the trauma intensive care unit (ICU) or trauma step-down units with&#xD;
      a fracture of the ribs, face, extremities and/or pelvis.&#xD;
&#xD;
      Eligible patients who signed the informed consent were randomized to either IV Ibuprofen&#xD;
      (Caldolor®) or Placebo via a computer-generated randomization list.&#xD;
&#xD;
      Patients had pain measured using a Numerical Rating Scale (NRS) that ranged from 0 (no pain)&#xD;
      to 10 (worst possible pain)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2012</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>, randomized, double-blind, parallel-group, placebo-controlled study. Eligible patients who signed the informed consent were randomized to either IV Ibuprofen (Caldolor®) or Placebo via a computer-generated randomization list.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Staff, including the principal investigator, study coordinator, and trauma nurses and the patients were blinded as to the treatment they received. In order to maintain the double-blind protocol, all IV bags had identical appearance and label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of IV Ibuprofen in Orthropedic Trauma Patients</measure>
    <time_frame>morphine equivalent dosage in over 48 hours after admission</time_frame>
    <description>Outcome measure based on morphine equivalent dosage comparing the two groups</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>IV Ibuprofen 800 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Ibuprofen 800 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Ibuprofen</intervention_name>
    <arm_group_label>IV Ibuprofen 800 mg</arm_group_label>
    <other_name>IV Caldolor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>IV Saline</arm_group_label>
    <other_name>iv saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Trauma patient admitted to Trauma ICU or Trauma Step-Down Units.&#xD;
&#xD;
          2. Fracture of ribs, face, extremities and/or pelvis&#xD;
&#xD;
          3. Age between 18 and 75 years old&#xD;
&#xD;
          4. Adequate IV access&#xD;
&#xD;
          5. Able to self report and communicate pain severity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergy or hypersensitivity to any component of IV Ibuprofen, aspirin (or&#xD;
             aspirin related products) NSAIDs, or COX-2 inhibitors&#xD;
&#xD;
          2. Any intracranial or spinal cord trauma&#xD;
&#xD;
          3. History of clinically significant bleeding disorders including ITP, DIC or platelet&#xD;
             dysfunction&#xD;
&#xD;
          4. Recent history of intracranial surgery or stroke (within past 30 days)&#xD;
&#xD;
          5. History of ulcers, gastritis or previous GI bleeding&#xD;
&#xD;
          6. Renal Impairment (Creatinine &gt; 3.0 mg/dL)&#xD;
&#xD;
          7. Pregnant or breastfeeding&#xD;
&#xD;
          8. Otherwise unsuitable in the opinion of the treating physician at time of&#xD;
             randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Russell Weisz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Delray Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Delray Medical Center</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bayouth L, Safcsak K, Cheatham ML, Smith CP, Birrer KL, Promes JT. Early intravenous ibuprofen decreases narcotic requirement and length of stay after traumatic rib fracture. Am Surg. 2013 Nov;79(11):1207-12.</citation>
    <PMID>24165259</PMID>
  </reference>
  <reference>
    <citation>Drendel AL, Lyon R, Bergholte J, Kim MK. Outpatient pediatric pain management practices for fractures. Pediatr Emerg Care. 2006 Feb;22(2):94-9.</citation>
    <PMID>16481924</PMID>
  </reference>
  <results_reference>
    <citation>Weisz RD, Fokin AA, Lerner V, Flynt A, Macias-Perez I, Pavliv L, Crawford M, Puente I. Intravenous Ibuprofen Reduces Opioid Consumption During the Initial 48 Hours After Injury in Orthopedic Trauma Patients. J Orthop Trauma. 2020 Jul;34(7):341-347. doi: 10.1097/BOT.0000000000001733.</citation>
    <PMID>31929374</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 16, 2014</study_first_submitted>
  <study_first_submitted_qc>May 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <results_first_submitted>February 8, 2021</results_first_submitted>
  <results_first_submitted_qc>July 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2021</results_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ibuprofen</keyword>
  <keyword>Caldolor</keyword>
  <keyword>orthopedic trauma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 9, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT02152163/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT02152163/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IV Ibuprofen 800 mg</title>
          <description>IV Ibuprofen 800 mg&#xD;
IV Ibuprofen</description>
        </group>
        <group group_id="P2">
          <title>IV Saline</title>
          <description>IV Saline&#xD;
placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IV Ibuprofen 800 mg</title>
          <description>IV Ibuprofen 800 mg&#xD;
IV Ibuprofen</description>
        </group>
        <group group_id="B2">
          <title>IV Saline</title>
          <description>IV Saline&#xD;
placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of IV Ibuprofen in Orthropedic Trauma Patients</title>
        <description>Outcome measure based on morphine equivalent dosage comparing the two groups</description>
        <time_frame>morphine equivalent dosage in over 48 hours after admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Ibuprofen 800 mg</title>
            <description>IV Ibuprofen 800 mg&#xD;
IV Ibuprofen</description>
          </group>
          <group group_id="O2">
            <title>IV Saline</title>
            <description>IV Saline&#xD;
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of IV Ibuprofen in Orthropedic Trauma Patients</title>
          <description>Outcome measure based on morphine equivalent dosage comparing the two groups</description>
          <units>morphine equivalent dosage, mg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" lower_limit="62.1" upper_limit="87.8"/>
                    <measurement group_id="O2" value="97.8" lower_limit="84.4" upper_limit="111.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <desc>No adverse events identified</desc>
      <group_list>
        <group group_id="E1">
          <title>IV Ibuprofen 800 mg</title>
          <description>IV Ibuprofen 800 mg&#xD;
IV Ibuprofen</description>
        </group>
        <group group_id="E2">
          <title>IV Saline</title>
          <description>IV Saline&#xD;
placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Russell Weisz, MD</name_or_title>
      <organization>Delray Medical Center</organization>
      <phone>561-213-9371</phone>
      <email>rdweisz@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

